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Background
During the course of HIV-1 infection, the status of
immune activation is associated with disease progression.
The immune system has adopted self-regulatory mecha-
nisms to counterbalance undesirable immune activation.
Regulatory T cells (TReg) expressing FoxP3 and CD4+ T
cells expressing IL-17 (TH17) play an important role in
this phenomenon. We hypothesized that a have couter-
balance of TH17 and TReg cells is found in subjects pro-
gressing to immunodeficiency.
Methods
Twenty-six individuals HIV-1-infected subjects were ana-
lysed pre and post antiretroviral treatment. PBMC were
stained and run using a 6-color flow cytometer to evaluate
immunophenotyping of forkhead box P3 (Foxp3), and
the activation status. PBMC with or without phorbol myr-
istate acetate (PMA) and ionomycin stimulation were
evaluated using a combination of markers (CD4, CD3, IL-
17, IL-2, TNF-α and IFN-).
Results
Data points were compared using non-parametric meth-
ods. The pre-treatment sampes tended to have lower
TRegs and TH17 cells compared to post-treatment sam-
ples. Pre- and post-treatment T cell activation levels, as
measured by the expression of HLADR+CD38+CD69+ on
CD4+ T cells (2.5 [1.6 – 3.4] vs. 1.4 [0.8 – 1.7], respec-
tively, p < 0.01) and CD38+HLADR+ on CD8+ T cells
(42.90 [31.35 – 50.75] vs. 17.50 [8.65 – 23.95], respec-
tively, p < 0.0001) cells was higher in pre-treatment sam-
ples. The levels of CD4+ T cell activation, measured by
CD69 expression, was positively associated with the fre-
quency of TH17 cells (r = 0.72, p < 0.001), but negatively
associated with the frequency of TRegs (r = -0.53, p <
0.05), both measured in the pre-treatment, which was lost
after the initiation of antiretroviral drugs.
Conclusion
TRegs and TH17 cells have opposite effects on T cell acti-
vation in HIV-infected subjects who are progressing to
immunodeficiency, but this counterbalance is overshad-
owed by the initiation of antiretroviral therapy. These
results suggest that the intense activation seen with the
progression to immunodeficiency is largely reflected in
the peripheral blood of such patients.
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